Navigation Links
New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
Date:4/19/2013

DURHAM, N.C., April 19, 2013 /PRNewswire/ -- A recent study funded by Centers for Disease Control and Prevention (CDC) Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.

It is well-documented that these pathogens, along with others such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), can persist on environmental surfaces for days or weeks, and C. diff. spores can exist as long as five months on surfaces in hospital environments. Standard approaches to environmental cleaning have proven inadequate with studies showing that 50 percent or more of hospital surfaces go untouched during terminal room disinfection, leading to the transmission of these hardy pathogens from one patient to another. The data published by the Society of Healthcare Epidemiology of America (SHEA) concluded that an automated UV-C system capable of delivering a measured and consistent UV-C dose significantly improved terminal disinfection of patient areas in hospitals.

The only device utilized in the study is TRU-D SmartUVC™, a portable UV disinfection system unique to the market with Sensor360™ technology, which analyzes the unique contents, shape and size of the room to calculate the precise pathogen-lethal dose of UV-C light needed to properly disinfect the environment (both line-of-site and shadowed spaces). A proper dose of UV-C light modifies the DNA structure of an infectious cell so it cannot reproduce and therefore cannot colonize and spread. These results were confirmed by the study, which reported a significant decrease in the total number of colony-forming units (CFUs) of these pathogens in both direct and indirect line of sight.

"Results of TRU-D have been supported by multiple independent peer-reviewed studies conducted by leading authorities in infection control and epidemiology," said Chuck Dunn , president of Memphis-based Lumalier, maker of TRU-D SmartUVC. "We are pleased to add another reputable third-party validation of our method of automated no-touch disinfection."

The study was performed at two tertiary acute care hospitals, Duke University Medical Center and University of North Carolina Health Care, from July 2011 through September 2011. Hospital rooms utilized in the study were identified as those of patients placed on precautions as a result of colonization or infection with a target organism. Environmental cultures – from direct and indirect lines of site – were obtained on specific environmental locations within the room after patient discharge and before manual room cleaning by housekeeping personnel. TRU-D was then used in the room, and cultures were repeated in triplicate from the same environmental sites following application of the UV-C light. In total, 229 environmental surfaces were sampled in the rooms of 39 patients over the 15-month study. Following use of TRU-D, there was a calculated reduction of more than 91 percent in the total number of CFUs of any pathogen detected from all sampled sites. Additionally, a greater than 92-percent reduction was achieved for all three target organisms (97.89 percent for VRE, 92.95 percent for C. diff. and 98.07 percent for Acinetobacter), with no statistically significant differences in reductions occurring in direct versus indirect line of sight disinfection for any of these categories.

TRU-D SmartUVC™, the signature product of Memphis-based Lumalier, is the only portable UV disinfection system on the market that precisely measures reflected UVC emissions with Sensor360™ to automatically calculate the pathogen-lethal UV dose required for proper and consistent disinfection of health care environments. For information, visit www.TRU-D.com.

For more information, contact:
Kerri Guyton
Obsidian Public Relations
Phone: 662-422-8012
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Lumalier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... , ... Beleza Medspa has initiated a new program to assist ... first time that Coolsculpting is being used for for more than just cosmetic purposes. ... meet the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
Breaking Medicine News(10 mins):